Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.

Published in:

Biomarker Research, 2021, v. 9, n. 1, p. 1, doi. 10.1186/s40364-021-00273-0

By:

• Kaneko, Yutaro;
• Hatano, Ryo;
• Hirota, Naoto;
• Isambert, Nicolas;
• Trillet-Lenoir, Véronique;
• You, Benoit;
• Alexandre, Jérôme;
• Zalcman, Gérard;
• Valleix, Fanny;
• Podoll, Thomas;
• Umezawa, Yoshimi;
• Takao, Seiichi;
• Iwata, Satoshi;
• Hosono, Osamu;
• Taguchi, Tetsuo;
• Yamada, Taketo;
• Dang, Nam H.;
• Ohnuma, Kei;
• Angevin, Eric;
• Morimoto, Chikao

Publication type:

Article